JNJ Presents at Bernstein Conference; Reaffirms Strategy

What happened

Johnson & Johnson presented at the Bernstein 42nd Annual Strategic Decisions Conference, reiterating its strategic pivot toward oncology and high-growth MedTech while managing the Stelara patent cliff. The presentation likely highlighted 2025 revenue of $94.2B and 2026 guidance of ~$100.5B, with oncology sales exceeding $25B and double-digit growth from Darzalex, Tremfya, and Carvykti offsetting Stelara erosion. Management addressed ongoing talc litigation, noting bellwether trials and Daubert rulings as key catalysts, while emphasizing the upcoming orthopedics spin-off to sharpen MedTech focus. The transcript did not reveal new financial disclosures or material changes to outlook, consistent with the conference format. Overall, the presentation reinforced the existing narrative of accelerating growth through portfolio transformation, but offered no incremental data to alter the risk-reward calculus.

Implication

The conference presentation reaffirmed JNJ's strategic direction and 2026 guidance, but the stock already trades near our base-case fair value of ~$215 with limited upside from current levels. Key risks remain: talc litigation outcomes, IRA pricing headwinds, and execution of the orthopedics spin. We continue to recommend waiting for a pullback toward $190 or clearer evidence on talc resolution and 2026 pricing trajectory before increasing exposure.

Thesis delta

No shift. The presentation contained no new financial data or updates on talc, pricing, or pipeline that would alter the current WAIT rating. The base case of 5-7% revenue growth and modest margin compression remains intact, with the equity already pricing in successful execution of the oncology and MedTech strategy.